MRNS - Marinus Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.76
+0.19 (+2.89%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.57
Open6.60
Bid6.56 x 800
Ask6.98 x 800
Day's Range6.43 - 6.79
52 Week Range1.27 - 9.87
Volume1,220,434
Avg. Volume737,812
Market Cap273.92M
Beta3.23
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire3 days ago

    Marinus Pharmaceuticals to Be Added to the Russell 2000 and Russell 3000 Index

    “We are pleased with Marinus’ addition to the Russell indexes,” said Christopher M. Cashman, Chief Executive Officer of Marinus. Russell US Indexes are the leading US equity benchmarks for institutional investors.

  • GlobeNewswire5 days ago

    Marinus Pharmaceuticals Initiates Pivotal Phase 3 Trial in Children with CDKL5 Deficiency Disorder

    Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the initiation of a pivotal Phase 3 clinical trial (Marigold Study) evaluating the use of oral ganaxolone in children and young adults with CDKL5 Deficiency Disorder (CDD). “We are excited to offer the CDKL5 patient community, for the first time, participation in a pivotal study of ganaxolone that may have the potential to reduce the seizure burden of the disorder,” said Christopher M. Cashman, Chief Executive Officer of Marinus.

  • GlobeNewswire8 days ago

    Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

    Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 90,000 shares of its common stock to two new employees, with a grant date of June 14, 2018. The stock options were granted as inducements material to the new employees entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant. Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders.

  • ACCESSWIRE9 days ago

    Free Technical Reports on MannKind and Three Additional Biotech Equities

    This morning, WallStEquities.com is focused on the Biotech space, which is engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development. Under evaluation today are these four equities: Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), MannKind Corp. (NASDAQ: MNKD), Marinus Pharmaceuticals Inc. (NASDAQ: MRNS), and Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT).

  • GlobeNewswire25 days ago

    Marinus Pharmaceuticals to Present at Upcoming Investor Conferences

    Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders. Ganaxolone is a positive allosteric modulator of GABAA that acts on a well-characterized target in the brain known to have both anti-seizure and anti-anxiety effects.

  • ACCESSWIRE26 days ago

    Mayo Clinic-Backed NMTC Could Be Worth 3X This Year

    For 1/3 of epilepsy patients, drugs won't control their seizures. Surgery may be an option (curative for some patients) but figuring out on what part of the brain to operate may require major brain surgery first: costly and invasive. This kind of event could put a lot of eyeballs on NMTC, and the stock has room to run as it goes through its first price discovery period.

  • GlobeNewswirelast month

    Marinus Pharmaceuticals to Present at the UBS Global Healthcare Conference

    Marinus Pharmaceuticals, Inc. (MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Christopher M. Cashman, Chief Executive Officer of Marinus, will present a company overview at the UBS Global Healthcare Conference on Monday, May 21, 2018 at 10:00 a.m. ET.  The conference will take place in New York. Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders.

  • GlobeNewswirelast month

    Consolidated Research: 2018 Summary Expectations for STORE Capital, Microvision, International Game Technology, McKesson, Marinus Pharmaceuticals, and Alnylam Pharmaceuticals — Fundamental Analysis, Key Performance Indications

    NEW YORK, May 11, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of STORE ...

  • GlobeNewswire2 months ago

    Marinus Pharmaceuticals Provides Business Update and First Quarter 2018 Financial Results

    Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the first quarter ended March 31, 2018. “Our team is laser-focused on enrolling our studies in women with postpartum depression and preparing the medical community for a soon-to-initiate global phase 3 pivotal study in children with CDKL5 deficiency disorder,” commented Christopher M. Cashman, chairman and chief executive officer of Marinus.

  • ACCESSWIRE6 months ago

    Today’s Research Reports on Trending Tickers: ImmunoCellular Therapeutics and Marinus Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / December 15, 2017 / Progress of the recent tax bill hit a snag on Thursday as two GOP Senators raised some concerns. All sectors closed down on Thursday dragging markets lower, ...

  • ACCESSWIRE7 months ago

    Today’s Research Reports on Stocks to Watch: Marinus Pharmaceuticals, Inc. and Otonomy, Inc.

    NEW YORK, NY / ACCESSWIRE / November 10, 2017 / Shares of Marinus Pharmaceuticals closed up 14% higher on Thursday after SAGE Therapeutics revealed positive clinical trial data for a postpartum depression ...

  • ACCESSWIRE9 months ago

    Today's Research Reports on Stocks to Watch: Marinus Pharmaceuticals and Teva Pharmaceutical Industries

    NEW YORK, NY / ACCESSWIRE / September 12, 2017 / Marinus Pharmaceuticals and Teva both got a big boost in trading price yesterday for different reasons. Teva has finally found a new CEO and announced the ...

  • ACCESSWIRE10 months ago

    Today's Research Reports on Stocks to Watch: Marinus Pharmaceuticals and CEL-SCI Corporation

    NEW YORK, NY / ACCESSWIRE / August 15, 2017 / It was a big trading day for both Marinus Pharmaceuticals and CEL-SCI Corporation on Monday. CEL-SCI shares were on the rampage to a new high after the FDA ...